Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Daré Bioscience stock | $1.34

Own Daré Bioscience stock in just a few minutes.

Fact checked

Daré Bioscience, Inc is a biotechnology business based in the US. Daré Bioscience shares (DARE) are listed on the NASDAQ and all prices are listed in US Dollars. Daré Bioscience employs 15 staff and has a market cap (total outstanding shares value) of USD$53.6 million.

How to buy shares in Daré Bioscience

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Daré Bioscience. Find the stock by name or ticker symbol: DARE. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Daré Bioscience reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.34, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Daré Bioscience, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Daré Bioscience. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Daré Bioscience share price

Use our graph to track the performance of DARE stocks over time.

Daré Bioscience shares at a glance

Information last updated 2020-12-26.
Latest market closeUSD$1.34
52-week rangeUSD$0.75 - USD$1.78
50-day moving average USD$1.2597
200-day moving average USD$1.1217
Wall St. target priceUSD$5.58
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.054

Buy Daré Bioscience shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Daré Bioscience stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Daré Bioscience price performance over time

Historical closes compared with the close of $1.34 from 2020-12-31

1 week (2021-01-15) -6.94%
1 month (2020-12-23) -6.94%
3 months (2020-10-22) 34.00%
6 months (2020-07-22) 9.84%
1 year (2020-01-22) -21.18%
2 years (2019-01-22) 63.39%
3 years (2018-01-22) 2.23
5 years (2016-01-22) 2.39

Daré Bioscience financials

Gross profit TTM USD$-533,334
Return on assets TTM -247.13%
Return on equity TTM -10764.21%
Profit margin 0%
Book value $0.022
Market capitalisation USD$53.6 million

TTM: trailing 12 months

Shorting Daré Bioscience shares

There are currently 522,611 Daré Bioscience shares held short by investors – that's known as Daré Bioscience's "short interest". This figure is 51.1% up from 345,861 last month.

There are a few different ways that this level of interest in shorting Daré Bioscience shares can be evaluated.

Daré Bioscience's "short interest ratio" (SIR)

Daré Bioscience's "short interest ratio" (SIR) is the quantity of Daré Bioscience shares currently shorted divided by the average quantity of Daré Bioscience shares traded daily (recently around 1.5 million). Daré Bioscience's SIR currently stands at 0.36. In other words for every 100,000 Daré Bioscience shares traded daily on the market, roughly 360 shares are currently held short.

However Daré Bioscience's short interest can also be evaluated against the total number of Daré Bioscience shares, or, against the total number of tradable Daré Bioscience shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Daré Bioscience's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Daré Bioscience shares in existence, roughly 10 shares are currently held short) or 0.0144% of the tradable shares (for every 100,000 tradable Daré Bioscience shares, roughly 14 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Daré Bioscience.

Find out more about how you can short Daré Bioscience stock.

Daré Bioscience share dividends

We're not expecting Daré Bioscience to pay a dividend over the next 12 months.

Have Daré Bioscience's shares ever split?

Daré Bioscience's shares were split on a 1:10 basis on 20 July 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Daré Bioscience shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Daré Bioscience shares which in turn could have impacted Daré Bioscience's share price.

Daré Bioscience share price volatility

Over the last 12 months, Daré Bioscience's shares have ranged in value from as little as $0.75 up to $1.78. A popular way to gauge a stock's volatility is its "beta".

DARE.US volatility(beta: 1.8)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Daré Bioscience's is 1.8017. This would suggest that Daré Bioscience's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Daré Bioscience overview

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company intends to develop therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single application that completed Phase 3 clinical trials; Ovaprene, a hormone-free, monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone replacement therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214 injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is based in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site